Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Katsuyuki Hotta, Edward B. Garon et al.|The Lancet Oncology|2019Cited by 617
Metronomic Oral Vinorelbine in Advanced Breast Cancer and Non-Small-Cell Lung Cancer: Current Status and Future DevelopmentMarina Elena Cazzaniga, Guido Bocci, Andrea Camerini et al.|Future Oncology|2015Cited by 54
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout durationDiana Ferraro, Carlo Pozzilli, Francesca Vitetta et al.|Journal of Neurology|2021Cited by 10
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective studyÉlisa Gobbini, Silvia Novello, Rita Chiari et al.|Clinical & Translational Oncology|2019Cited by 5
MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.Élisa Gobbini, Silvia Novello, Pamela Pizzutilo et al.|Journal of Thoracic Oncology|2018Cited by 1